Breast cancer is a heterogeneous disease comprised of four molecular subtypes defined by whether the tumor-originating cells are luminal or basal epithelial cells. Breast cancers arising from the lumi
We report transcriptome profiling (RNA-seq) for SMARA4 knock-out to elucidate the association with cisplatin-resistance and SMARCA4 loss-of-function using triple negative breast cancer cell lines. Ove
Triple negative breast cancer (TNBC) represents a challenging tumor type due to their poor prognosis and limited treatment options. It is well recognize that clinical and molecular heterogeneity of TN
Chemotherapy and macrophage depletion leads to T cell memory activation and durable triple negative breast cancer regression in p53 null mouse models. Overall design: RNA-seq was performed on 15 'p53
